Promising results for venetoclax combination therapies in elderly AML

AML Treatment Challenges Who, When, and HowПодробнее

Venetoclax Combination Therapy and Elderly AML PatientsПодробнее

Oral combination of HMAs + venetoclax in unfit or elderly patients with AMLПодробнее

Venetoclax combinations effective in elderly AMLПодробнее

Current research in elderly, untreated AML: venetoclax combinationsПодробнее

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungalsПодробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

Venetoclax in combination with low-dose cytarabine – a promising regimen for the treatment of AMLПодробнее

CAVEAT: venetoclax and high dose chemo for elderly AMLПодробнее

Venetoclax for elderly AML patientsПодробнее

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”Подробнее

Treating older patients with AML in 2020: What is new and promising?Подробнее

Venetoclax Combination in the Frontline Setting for AMLПодробнее

Venetoclax, CLAD/LDAC and azacitdine in older AML patientsПодробнее

Venetoclax combination therapies in AMLПодробнее

Venetoclax based combination therapy in AML: a real-world retrospective analysisПодробнее

Preliminary promise for venetoclax and 3+7 in untreated AMLПодробнее

Update on venetoclax combination trials for elderly AML from ASH 2017Подробнее

Promising outlooks for venetoclax combinations for MMПодробнее

Venetoclax plus CLAD/LDAC and aza for older AML patientsПодробнее